Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Milestone Pharmaceuticals (Nasdaq: MIST) granted a total of 30,000 stock options as inducement awards to two newly hired employees under its 2021 Inducement Plan, with a grant date of December 1, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Milestone Pharmaceuticals (Nasdaq: MIST) granted a total of 30,000 stock options as inducement awards to two newly hired employees under its 2021 Inducement Plan, with a grant date of December 1, 2025.
The options have an exercise price of $2.69 per share (equal to the closing price on the grant date) and vest over four years: 25% at the one-year anniversary and the remainder in 36 equal monthly installments. Awards are subject to continuous service and standard plan terms and were made in accordance with Nasdaq Listing Rule 5635(c)(4).
Details
News Market Reaction – MIST
On Dec 3, the first trading day after this news, MIST closed 1.13% below the previous close.
Data tracked by StockTitan Argus for the Dec 3 session.
Key Figures
- Inducement options
- 30,000 options
- Granted under 2021 Inducement Plan to two new employees
- Exercise price
- $2.69 per share
- Option exercise price equal to Dec 1, 2025 close
- Vesting period
- 4 years
- 25% after one year, remainder over 36 monthly installments
- Net loss Q3 2025
- $11.9 million
- Quarter ended September 30, 2025 (10-Q)
- Net loss 9M 2025
- $45.6 million
- Nine months ended September 30, 2025 (10-Q)
- Cash & investments
- $82.6 million
- Cash, equivalents and short-term investments as of Sept 30, 2025
- Senior convertible notes
- $56.2 million
- Net carrying amount as of Sept 30, 2025 (10-Q)
Historical Context
-
30,000 stock options granted as inducement awards to two new hires.
-
Q3 2025 results, cash of $82.6M and PDUFA date for CARDAMYST.
-
65,000 stock options granted under 2021 Inducement Plan for new hires.
-
Pooled etripamil PSVT data showing consistent efficacy and safety across trials.
-
Announcement of upcoming AHA 2025 poster on etripamil efficacy and safety.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
MONTREAL and CHARLOTTE, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 30,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of two new employees.
The Options have a grant date of December 1, 2025, and an exercise price of
The Option awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Plan and its standard forms of grant agreements thereunder.
The foregoing equity award was granted as an inducement material to the employee entering into employment with Milestone, in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Milestone, or following a bona fide period of non-employment, as an inducement material to such individual’s entering into employment with Milestone, pursuant to Nasdaq Listing Rule 5635(c)(4).
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.
Contact:
Kevin Gardner kgardner@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.